Send to

Choose Destination
Clin Rheumatol. 2014 Jan;33(1):137-9. doi: 10.1007/s10067-013-2435-8. Epub 2013 Nov 28.

Survey about tolerance of the AS03-adjuvanted H1N1 influenza vaccine in children with rheumatic diseases.

Author information

Epidemiology Unit, German Rheumatism Research Centre Berlin, Leibniz Institute, Charitéplatz 1, 10117, Berlin, Germany,


The objective of this study is to evaluate complications and changes in health status (disease activity and flare) in response to the AS03-adjuvanted H1N1 vaccine in children with rheumatic diseases. We conducted a nationwide survey addressing paediatric rheumatology sites who participated in the national paediatric rheumatology database. Ninety patients were documented-38 % under treatment with biologicals-of whom 18 % suffered from complications (10 % local and 8 % systemic) with no relevant changes in median disease activity or flare rate during 4 weeks following the vaccination. The adjuvanted H1N1 influenza vaccine seems to be adequately tolerated in children with rheumatic diseases.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center